GlassScriptPhysician profile
James T Crabtree
NPI 1538188818
$984.25
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $526 · 2020: $443 · 2022: $14.91.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $292.41 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $236.91 | 2019-2020 | |
| Amgen INC. | $83.24 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $62.44 | 2019 | |
| Astellas Pharma US INC | $55.89 | 2019 | |
| Eisai INC. | $46.84 | 2020 | |
| Allergan, INC. | $38.10 | 2019 | |
| Novartis Pharmaceuticals Corporation | $33.32 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $29.24 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.38 | 2019 | |
| Jazz Pharmaceuticals INC. | $17.52 | 2020 | |
| Nabriva Therapeutics, Plc | $17.48 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.74 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.91 | 2022 | |
| Esperion Therapeutics, INC. | $11.83 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Crabtree listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.